PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)-- Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug ...

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized, ...

Extension of study evaluated safety and efficacy of dapagliflozin plus metformin versus placebo plus metformin at 102 weeks Update on overall safety profile provided In addition to sustained ...

Adding an investigational nonsteroidal mineralocorticoid receptor antagonist (MRA) to an SGLT2 inhibitor led to a superior ...

NEW ORLEANS, LA—Sodium-glucose cotransporter 2 (SGLT2) inhibition does not seem to be a solution to the problem of arrhythmia ...

The DAPPER study was conducted with the National Cardiovascular Center as the principal investigator, with 294 patients participating from 18 facilities in Japan. In this study, we investigated ...

Authors report theirs is the first real-world study comparing the 2 SGLT2 inhibitors. A recently published study that compared patients with type 2 diabetes (T2D) taking the highest dose of ...

African American Woman Tests Blood Sugar. Blood sugar is slightly high. A large multinational study examined the potential impact of dapagliflozin on kidney disease in people with type 2 diabetes.

WILMINGTON, Del.--(BUSINESS WIRE)--Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), ...

BOSTON -- The SGLT-2 inhibitor dapagliflozin (Farxiga) was tied to a suppression in plasma hepcidin concentrations in patients with type 2 diabetes, researchers reported here. Compared with baseline, ...